

Evidence-Based Lung Cancer Treatment Algorithmic Tests

- I. Lung cancer treatment algorithmic tests with sufficient evidence of clinical validity and utility are considered **medically necessary** when:
 - A. The member has a non-squamous non-small cell lung cancer (NSCLC), **AND**
 - B. The member's tumor size is less than 5 cm, **AND**
 - C. The member has no positive lymph nodes (stages I and IIa), **AND**
 - D. The member is considering adjuvant platinum-containing chemotherapy.
- II. Lung cancer treatment algorithmic tests with sufficient evidence of clinical validity and utility are considered **investigational** for all other indications where clinical validity and utility have not been demonstrated.

RATIONALE AND REFERENCES

Evidence-Based Lung Cancer Treatment Algorithmic Tests

Centers for Medicare and Medicaid Services (CMS)

The CMS local coverage determination (LCD) entitled “MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer” includes the following coverage criteria for lung cancer treatment algorithmic tests:

- “The patient has a non-squamous NSCLC with a tumor size < 5cm, and there are no positive lymph nodes (i.e., American Joint Committee on Cancer (AJCC) Eighth Edition Stages I and IIa)
- The patient is sufficiently healthy to tolerate chemotherapy
- Adjuvant platinum-containing chemotherapy is being considered for the patient”.

Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (L38238). Available at: <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38238>

DEFINITIONS

1. **ABCDE feature** is an acronym for examining patients with a lesion that is suspicious for melanoma: **a**symmetry, **b**order irregularity, **c**olor variegation, **d**iameter greater than 6 mm, and **e**volution.
2. **Adjuvant** therapy is a medication (such as chemotherapy or endocrine therapy) given after the surgical removal of a cancerous tumor.
3. **Ductal/NST** is a ductal breast cancer of no special type (NST), meaning the cancer cells have no features that classify them as a specific type of breast cancer when examined by microscope.
4. **Indeterminate cytologic findings** include Bethesda diagnostic category III (atypia/follicular lesion of undetermined significance) or Bethesda diagnostic category IV (follicular neoplasm/suspicion for a follicular neoplasm)